Non convulsive refractory status epilepticus induced by thiocolchicoside (TCC) intrathecal injection: A case report

Br J Clin Pharmacol. 2022 Jul;88(7):3495-3499. doi: 10.1111/bcp.15240. Epub 2022 Feb 8.

Abstract

TCC is a semisynthetic molecule widely used in clinical settings as a pain killer and myorelaxant. Several neurological side effects have been reported in association with TCC treatment including somnolence, confusion and seizure, the latter in a lower percentage of patients. Some previous reports described seizure onset after TCC intake in adulthood. However, major epileptological complication, namely status epilepticus, has never been previously reported in association with TCC treatment. In our report, we describe a case of acute refractory non-convulsive status epilepticus (NCSE) in the context of a TCC-induced acute toxic encephalopathy (ATE) in a woman without any previous neurological or physical comorbidities.

Keywords: acute toxic encephalopathy; amnesia; case report; non-convulsive status epilepticus; thiocolchicoside.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Colchicine / adverse effects
  • Colchicine / analogs & derivatives
  • Electroencephalography
  • Female
  • Humans
  • Injections, Spinal / adverse effects
  • Seizures / drug therapy
  • Status Epilepticus* / chemically induced
  • Status Epilepticus* / complications
  • Status Epilepticus* / drug therapy

Substances

  • Colchicine
  • thiocolchicoside